Use of Yttrium-90 microspheres (TheraSphere®) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: A case report

Laura M. Kulik, Mary F. Mulcahy, Russell D. Hunter, Albert A. Nemcek, Michael M. Abecassis, Riad Salem*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Prior to therapy, model for end stage liver disease (MELD) scoring, diagnostic imaging and tumor staging were performed in a patient with T3 HCC. The patient received an orthotopic liver transplant (OLT) 42 days after treatment. The explant specimen showed complete necrosis of the target tumor. Follow-up of this patient has demonstrated no evidence of recurrence. There was no life threatening or fatal adverse experiences related to treatment. This case report documents the natural course, history and outcome of a patient treated with yttrium-90 for unresectable HCC. The patient was downstaged from T3 to T2 and was subsequently transplanted.

Original languageEnglish (US)
Pages (from-to)1127-1131
Number of pages5
JournalLiver Transplantation
Volume11
Issue number9
DOIs
StatePublished - Sep 2005

ASJC Scopus subject areas

  • Surgery
  • Hepatology
  • Transplantation

Fingerprint Dive into the research topics of 'Use of Yttrium-90 microspheres (TheraSphere®) in a patient with unresectable hepatocellular carcinoma leading to liver transplantation: A case report'. Together they form a unique fingerprint.

Cite this